The New Vision / AllAfrica.

The New Vision / reports J has extended the right to join the antiretroviral program by increasing the eligible CD4+ T – cell count of 350 of 200. Nathan Kenya, clinical and community health services director, said that previous registration criteria were ‘always fair'(Buryegyeya, New Vision / AllAfrica.

Also the platform for attachment of peptides and other targeting molecules for delivery to a variety of tissues is possible , and thus for various therapeutic view.. About the DiLA2 Delivery PlatformThe DiLA2 Delivery Platform is MDRNA proprietary platform for creating novel liposomal delivery systems on di – alkylated amino acids is based. The DiLA2 platform enables MDRNA to tailor the charge, linker length, and acyl chain characteristics, the delivery of the liposomes to target tissue of interest to improve. In vivo studies of effective delivery in models of metabolic disorders, cancer and other diseases have been established. DiLA2 based liposomes are well tolerated in repeated dose and systemic and local administration. MDRNA also using condensing peptides to peptide-siRNA nanoparticles form for further increasing the efficiency of the delivery DiLA2 delivery systems.Times courtesy You may emphasis the complete royal Daily Health Policy Report display looking for or, or sign up for mail service in Imperial Daily Health Policy Report being. Releases on kaiser network. A free service of the Henry J. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

Other entries from category "gynecology":

Tag Cloud